RecruitingNot ApplicableNCT07543718

Group Medical Visits for Patients With Dyslipidemia

Improving Care Through Group Medical Visits for Patients With Dyslipidemia

Sponsor

Université de Sherbrooke

Enrollment

288 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Dyslipidemias

Summary

Physicians' interventions to promote the improvement of lifestyle habits have been shown to be effective. However, such interventions remain underutilized due to barriers such as lack of time, confidence, and compensation. Group medical visits (GMVs) can help overcome several of these barriers and effectively improve clinical indicators as well as patients' quality of life. GMVs could also reduce pressure on the healthcare system by improving access to primary care through a more efficient use of resources. The literature suggests that GMVs can be effective in improving access to care and reducing disease complications for patients with several conditions and risk factors, but they have not been assessed specifically among patients with dyslipidemia, which is at the origin of most cases of cardiovascular diseases. In this context, GMVs will be implemented among 144 patients with dyslipidemia. The objective for this project is to evaluate implementation of GMVs. The implementation evaluation will follow the RE-AIM framework. These steps will position the research team to develop more complex and large-scale studies in lifestyle medicine. In the meantime, the project will contribute to improve access to primary care for the prevention of cardiovascular diseases.

Eligibility

Min Age: 40 Years

Inclusion Criteria1

Diagnosis of dyslipidemia according to the guidelines of the Canadian Cardiovascular Society, i.e., at a minimum: an intermediate cardiovascular risk according to the Framingham Risk Score (10-19.9%) WITH LDL-C ≥ 3.5 mmol/L or non-HDL-C ≥ 4.2 mmol/L or ApoB ≥ 1.05 g/L

Exclusion Criteria3

Patients unable to participate in GMV sessions or to provide informed consent
Patients with a mental health condition likely to limit their ability to benefit from GMV sessions and discussions (Examples: severe dementia or an acute psychiatric decompensation occurring within the past six months)
A diagnosis of terminal illness or a life expectancy of less than 12 months

Interested in this trial?

Get notified about updates and connect with the research team.